The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation.
Respiratory syncytial virus (RSV) is an important cause of acute respiratory disease in infants, immunocompromised subjects and the elderly. However, it is unclear why most primary RSV infections are associated with relatively mild symptoms, whereas some result in severe lower respiratory tract infections and bronchiolitis. Since RSV hospitalization has been associated with respiratory bacterial co-infections, we have tested if bacterial Toll-like receptor (TLR) agonists influence RSV-A2-GFP infection in human primary cells or cell lines. The synthetic bacterial lipopeptide Pam3-Cys-Ser-Lys4 (Pam3CSK4), the prototype ligand for the heterodimeric TLR1/TLR2 complex, enhanced RSV infection in primary epithelial, myeloid and lymphoid cells. Surprisingly, enhancement was optimal when lipopeptides and virus were added simultaneously, whereas addition of Pam3CSK4 immediately after infection had no effect. We have identified two structurally related lipopeptides without TLR-signaling capacity that also modulate RSV infection, whereas Pam3CSK4-reminiscent TLR1/2 agonists did not, and conclude that modulation of infection is independent of TLR activation. A similar TLR-independent enhancement of infection could also be demonstrated for wild-type RSV strains, and for HIV-1, measles virus and human metapneumovirus. We show that the effect of Pam3CSK4 is primarily mediated by enhanced binding of RSV to its target cells. The N-palmitoylated cysteine and the cationic lysines were identified as pivotal for enhanced virus binding. Surprisingly, we observed inhibition of RSV infection in immortalized epithelial cell lines, which was shown to be related to interactions between Pam3CSK4 and negatively charged glycosaminoglycans on these cells, which are known targets for binding of laboratory-adapted but not wild-type RSV. These data suggest a potential role for bacterial lipopeptides in enhanced binding of RSV and other viruses to their target cells, thus affecting viral entry or spread independent of TLR signaling. Moreover, our results also suggest a potential application for these synthetic lipopeptides as adjuvants for live-attenuated viral vaccines.
Nguyen
D Tien
DT
Department of Virology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
de Witte
Lot
L
Ludlow
Martin
M
Yüksel
Selma
S
Wiesmüller
Karl-Heinz
KH
Geijtenbeek
Teunis B H
TB
Osterhaus
Albert D M E
AD
de Swart
Rik L
RL
D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects / Q000378:metabolism / Q000472:pathogenicity; D006801:Humans; D055666:Lipopeptides / Q000737:chemistry / Q000494:pharmacology*; D008459:Measles virus / Q000187:drug effects / Q000378:metabolism / Q000472:pathogenicity; D029121:Metapneumovirus / Q000187:drug effects / Q000378:metabolism / Q000472:pathogenicity; D018357:Respiratory Syncytial Virus Infections / Q000378:metabolism* / Q000382:microbiology; D012136:Respiratory Syncytial Viruses / Q000187:drug effects / Q000378:metabolism* / Q000472:pathogenicity*; D051193:Toll-Like Receptors / Q000378:metabolism
D000276:Adjuvants, Immunologic; D055666:Lipopeptides; C508075:Pam(3)CSK(4) peptide; D051193:Toll-Like Receptors
Emerg Infect Dis. 2004 Jul;10(7):1318-20
15324559
Cell. 2007 Dec 14;131(6):1059-71
18083097
Arch Virol. 1978;56(3):227-36
565198
J Immunol. 2007 Oct 1;179(7):4357-66
17878330
Pediatrics. 2008 Aug;122(2):229-37
18676537
J Virol. 2002 Jul;76(13):6743-9
12050387
J Virol. 1999 Aug;73(8):6370-9
10400729
Mol Immunol. 2009 Mar;46(6):1084-91
19027958
J Immunol. 1972 Dec;109(6):1296-9
4343749
J Clin Invest. 2004 May;113(10):1473-81
15146245
J Immunol Methods. 2009 Dec 31;351(1-2):13-23
19804781
Am J Hyg. 1957 Nov;66(3):281-90
13478578
Pediatr Res. 2005 Dec;58(6):1198-203
16306193
Cell Microbiol. 2009 Sep;11(9):1399-408
19500108
Infect Immun. 2009 Feb;77(2):714-24
19015258
Cell. 2007 Sep 21;130(6):1071-82
17889651
Immunobiology. 1989 Nov;180(1):93-100
2625355
Histochem Cell Biol. 2003 Feb;119(2):103-8
12610729
Am J Hyg. 1957 Nov;66(3):291-300
13478579
Epidemiol Infect. 2008 Nov;136(11):1448-54
18211724
Retrovirology. 2009 May 06;6:42
19419540
J Virol. 2000 Nov;74(22):10508-13
11044095
Biochem Biophys Res Commun. 2009 Oct 30;388(4):621-5
19686699
J Clin Invest. 2008 Oct;118(10):3440-52
18776939
Biophys J. 2004 Feb;86(2):1234-42
14747357
Eur J Immunol. 2005 Jan;35(1):282-9
15580661
Pediatr Res. 2004 Jun;55(6):972-8
15103015
J Virol. 2006 Feb;80(4):1629-36
16439519
Nat Med. 2004 Aug;10(8):811-3
15247911
J Gen Virol. 1991 Nov;72 ( Pt 11):2685-96
1940866
Vaccine. 2000 Dec 8;19 Suppl 1:S51-5
11163463
J Virol. 2004 Aug;78(15):7867-73
15254159
Pediatr Pathol. 1990;10(4):491-502
1695371
J Immunol. 1990 Mar 15;144(6):2394-9
2107259
Clin Exp Immunol. 2004 Jul;137(1):8-11
15196237
J Med Virol. 2004 Jun;73(2):300-8
15122808
Immunol Cell Biol. 2007 Aug-Sep;85(6):463-70
17680012
Curr Opin Immunol. 2003 Feb;15(1):5-11
12495726
J Virol. 2010 May;84(9):4714-24
20181691
FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):189-95
10575129
Virology. 2000 Jun 5;271(2):264-75
10860881
Methods Mol Biol. 2007;379:15-34
17502668
J Infect. 2009 Jan;58(1):37-46
19042025
Clin Infect Dis. 2000 May;30(5):784-9
10816149
J Biol Chem. 2007 Jul 20;282(29):21145-59
17462991
Arch Dis Child. 2004 Dec;89(12):1155-7
15557055
Virology. 2002 May 10;296(2):204-11
12069519
Curr Opin Struct Biol. 2007 Aug;17(4):427-36
17870467
J Immunol. 2005 Jun 15;174(12):7995-8002
15944306
Clin Exp Allergy. 2008 Nov;38(11):1819-29
18644025
Lancet. 1999 Sep 4;354(9181):847-52
10485741
J Infect Dis. 2005 Feb 1;191(3):382-6
15633097
Vaccine. 2008 Jul 4;26(29-30):3735-41
18539368
J Virol. 2009 Jan;83(1):73-80
18945786
J Immunol. 2008 Sep 15;181(6):3823-33
18768836
Pediatr Infect Dis J. 1987 Dec;6(12):1134-5
3431985
J Virol Methods. 2007 Aug;143(2):169-74
17420056
Blood. 2009 May 21;113(21):5157-66
19279330